Study drug injection for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This Phase 1 trial tests VG161, a study medicine, given by injection into liver or nearby tumors for people with advanced primary liver cancer that has not responded to standard treatment (or there is no standard option). The goal is to find a safe dose and see how the tumors respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (hepatocellular carcinoma or certain related bile-duct cancers) that is relapsed/refractory to standard treatment, or no standard treatment exists—if enrolled in the later part, it must be hepatocellular carcinoma only.
- Your tumor has injectable spots in the liver or outside the liver that can be seen on ultrasound, with a minimum size (longest tumor diameter over 1.5 cm, or lymph node shortest diameter requirement).
- Your health status is good enough for a study visit (ECOG score 0 or 1).
- You can expect at least 3 months of life expectancy, based on your doctor’s judgment.
- Blood and organ tests must be within required ranges (including adequate liver, kidney, blood counts, and clotting).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
This trial tests a new treatment that uses a virus to attack tumor cells directly. It is for people with advanced pancreatic cancer that has not responded to standard therapy. The virus is injected into a tumor, and the goal is to see if it can shrink the cancer or slow its growth.
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, VG161 (a virus that targets cancer cells) and camrelizumab (an immunotherapy), for people with advanced liver cancer that has not responded to or stopped working after first-line treatment. It aims to see if this combination can shrink tumors and help patients live longer.
Hear when a new Primary Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.